1Lery D,Wilson P WF,Anderson KM et al.stratifying the patient at from coronary disease:New insight from Framingham heart study.Am Heart J,1990,119(10):712
2Giorda C,Appendino M.Effects of doxazosin,a selective α1-inhibitor,on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension.Metabolism,1993,42:1 440
3Daae LN,westlie L.A 5-year comparison of doxazosin and atenolol in patients with mild to moderate hypertension:effects on blood pressure,serum lipids,and coronary heart disease risk.Blood press,1998,7(1):39
4Elliott WJ,Black HR.Treatment of hypertension in the elderly.Am J Gardiol,2002,11(1):11
1[7]Vashisht R, Sian M, Franks PJ, et al. Long-term reduction of intimal hyperplasia by the selective alpha-1 adrenergic antagonist doxazosin. Br J Surg, 1992, 79: 1 285-288
3[2]Hu ZW, Shi XY, Okazaki M, et al. Angiotensin Ⅱ induces transcription and expression of α1 -adrenergic receptors in vascular soomth muscle cells. Am J Physiol, 1995, 268: H1 006-014
4[3]Hu ZW, Shi XY, Lin R, et al. α1-Adrenergic receptor subtypes: activation of phosphatidylinositol 3-kinase. Mol Biol Cell Suppl, 1995, 6: 128
5[4]Ulrich K, Shu W, Sarah K, et al. Doxazosin inhibits retinoblastoma protein phosphorylation and G1-S transition in human coronary smooth muscle cells. Arterioscler Thromb Vasc Biol, 2000, 20: 1 216-224
6[5]Kato JY, Matsuoka M, Polyak K, et al. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell, 1994, 79: 487-496
7[6]Laufs U, Marra D, Node K, et al. 3 Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem, 1999, 274: 21 926-931
